COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year.

ABSTRACT: COVID-19 is associated with a high incidence of thrombotic complications, which can be explained by the complex and unique interplay between coronaviruses and endothelial cells, the local and systemic inflammatory response, and the coagulation system. Empirically, an intensified dose of thrombosis prophylaxis is being used in patients admitted to hospital with COVID-19 and several guidelines on this topic have been published, although the insufficiency of high quality and direct evidence has led to weak recommendations. In this Viewpoint we summarise the pathophysiology of COVID-19 coagulopathy in the context of patients who are ambulant, admitted to hospital, and critically ill or non-critically ill, and those post-discharge from hospital. We also review data from randomised controlled tr

SUBMITTER: Leentjens J 

PROVIDER: S-EPMC8078884 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature